Immuno-oncology Archives | ChemPartner

TIL Subpopulation Screening in Syngeneic Models

<img data-src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" width="1080" height="675" data-srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img data-src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" width="1080" height="675" data-srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" class="" width="1080" height="675" srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" />

TIL Subpopulation Screening in Syngeneic Models

by Sarah Stapleton | Mar 5, 2021

TIL baselines were profiled in top ten popular tumor models: CT26.WT MC-38 4T1 B16-F10 EL4 EMT-6 Hepa1-6 A20 LLC1 Renca Data expressed are average values of 3 tumors of 500-1000 mm3 for each model. ...

Readouts and Methods – Ex Vivo Analysis

<img src="https://chempartner.com/wp-content/uploads/2021/02/Laser-confocal-scanning-microscopy-LCSM-1080x675.jpg" alt="Readouts and Methods – Ex Vivo Analysis" class="" width="1080" height="675" srcset="https://chempartner.com/wp-content/uploads/2021/02/Laser-confocal-scanning-microscopy-LCSM-980x667.jpg 980w, https://chempartner.com/wp-content/uploads/2021/02/Laser-confocal-scanning-microscopy-LCSM-480x327.jpg 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" />

Readouts and Methods – Ex Vivo Analysis

by Sarah Stapleton | Mar 5, 2021

Readouts Frequency of immune cell subpopulation Expression of immune checkpoints and markers Soluble factors Receptor Occupancy Methods Flow cytometry IHC, IF ELISA, Luminex, CBA ELISpot Western blot, qPCR Tissues Tumor Spleen Lymph nodes Peripheral blood...

TIL Subpopulation Screening in Syngeneic Models

<img data-src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" width="1080" height="675" data-srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img data-src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" width="1080" height="675" data-srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" class="" width="1080" height="675" srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" />

Case Study: Driving to Clinical Development

by Sarah Stapleton | Mar 5, 2021

MOA/Biomarker Cmpd X currently in clinical trials.

TIL Subpopulation Screening in Syngeneic Models

<img data-src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" width="1080" height="675" data-srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img data-src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" width="1080" height="675" data-srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" class="" width="1080" height="675" srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" />

Target-Specific Assay Panels – Small Molecule Targets

by Sarah Stapleton | Mar 5, 2021

ID Target Biochemical Assay Cell-based Assays 1 IDO1 IDO1 enzyme activity IFNγ-induced cellular IDO1 in Hela cells; IDO1 transient/stable transfection in HEK293 cells 2 TDO2 TDO2 enzyme activity TDO2 transient/stable transfection in HEK293 cells 3 ARG1 ARG1 enzyme...

TIL Subpopulation Screening in Syngeneic Models

<img data-src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" width="1080" height="675" data-srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img data-src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" width="1080" height="675" data-srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://chempartner.com/wp-content/uploads/2021/02/BP--1080x669.png" alt="TIL Subpopulation Screening in Syngeneic Models" class="" width="1080" height="675" srcset="https://chempartner.com/wp-content/uploads/2021/02/BP--980x364.png 980w, https://chempartner.com/wp-content/uploads/2021/02/BP--480x178.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" />

Target-Specific Assays – Antibody Targets

by Sarah Stapleton | Mar 5, 2021

ID Target Receptor Ligand Binding Blocking Cell-based Functional Readout 1 PD1 PD1/PD-L1 PD1/PD-L2 T cell activation (PBMC + CHOK1/OS8/PD-L1) Mixed Lymphocyte Reaction Jurkat NFAT luciferase reporter assay 2 PD-L1 PD-L1/PD1 PD-L1/B7.1 T cell activation (PBMC +...

Readouts and Methods – Ex Vivo Analysis

<img src="https://chempartner.com/wp-content/uploads/2021/02/Laser-confocal-scanning-microscopy-LCSM-1080x675.jpg" alt="Readouts and Methods – Ex Vivo Analysis" class="" width="1080" height="675" srcset="https://chempartner.com/wp-content/uploads/2021/02/Laser-confocal-scanning-microscopy-LCSM-980x667.jpg 980w, https://chempartner.com/wp-content/uploads/2021/02/Laser-confocal-scanning-microscopy-LCSM-480x327.jpg 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" />

Functional Assay Panels

by Sarah Stapleton | Mar 5, 2021

ID Assay Type Cell Type 1 Mixed Lymphocyte Reaction (MLR) Primary human/mouse DC + T cells 2 CMV antigen recall Primary human T cells 3 T cell activation (anti-CD3/CD28) Primary human/mouse T cells 4 T cell activation (SEB super-antigen) Primary human T cells 5 T...